Effect of CCR2-V64I on the Susceptibility of Patients to Cancer

Background. Results from the studies investigating the impact of CC chemokine receptor 2 (CCR2) polymorphism on the risk of cancers are diverse. An updated meta-analysis was conducted to access the relationship between cancer risk and CCR2-V64I polymorphism. Methods. We performed a meta-analysis using STATA 11.0 based on a comprehensive retrieval in WanFang Data, PubMed, China National Knowledge Infrastructure, EMBASE, and Web of Science databases up to January 20, 2023. Results. We included 23 studies in our analysis. Overall, we found CCR2-V64I polymorphism was remarkably related to cancer risk (OR = 1.39, 95% CI = 1.14–1.70, and P=0.001 for A vs G; OR = 1.87, 95% CI = 1.30–2.70, and P=0.001 for AA vs GG; OR = 1.35, 95% CI = 1.03–1.78, and P=0.032 for GA vs GG; OR = 1.45, 95% CI = 1.11–1.90, and P=0.006 for AA + GA vs GG; OR = 1.69, 95% CI = 1.20–2.37, and P=0.003 for AA vs GA + GG). In the ethnicity subgroup analysis, the relevancy between CCR2-V64I polymorphism and an increased cancer risk was discovered among Asians (OR = 1.57, 95% CI = 1.30–1.91, and P